Skip to content

Database / Amycretin

In Phase 3Amylin/GLP-1 unimolecular agonistInjection or oral · Weekly

Amycretin

No brand yet · Novo Nordisk. One molecule that activates both amylin and GLP-1 receptors. Early results showed about 22% weight loss at 36 weeks with no plateau.

Average weight loss
22%
Stopped for side effects
n/r
Trial length
36 wk
Ranking score
n/r

Phase 1b/2a results

Phase 1b/2a · 36 weeks · 20 mg weekly
Adults with obesity (small early trial)

Weight loss
22.0%
Nausea
n/r
Vomiting
n/r
Diarrhea
n/r
Constipation
n/r
Quit due to side effects
n/r

n/r = not reported.

Worth knowing

  • Stomach side effects were reported by 94% at the higher doses in the early trial.
–
Not yet ranked
Needs Phase 3 data. We rank only drugs with a completed Phase 3 trial and published side-effect rates.

At a glance

Company
Novo Nordisk
Targets
Amylin, GLP-1
Molecule
Peptide
Dosing
Injection or oral, weekly
Status
In Phase 3

Compare with another drug

Sources